Prevail Partners

Coologics is a clinical-stage medical device company specializing in drug-free solutions for vaginal yeast infections. Their primary product is a device that combines physical and mechanical interactions with the vaginal wall, time-controlled cooling to treat infections, alleviate symptoms, restore the vaginal microbiome and pH, and disrupt biofilms.

Triple Hair is a company focused on developing solutions for thinning hair and hair loss, specifically targeting conditions such as alopecia. The company offers a triple combination therapy that utilizes synergistic effectiveness to promote hair growth in men. This innovative approach aims to prevent hair loss while enhancing hair thickness and pigmentation. Through its topical hair growth therapies, Triple Hair addresses the needs of individuals seeking to improve their hair health and appearance.

Operator of a cancer immunotherapy company intended to develop medicines to treat primary, recurrent and metastatic cancers. The company uses several different technologies and approaches utilizing viral vectors and affinity agents that can be conjugated to deliver biologicals, enabling doctors to utilize new and advanced treatments to cure patients even in advanced stages of cancer.

HemoGenyx LLC is a biopharmaceutical company based in Brooklyn, New York, that specializes in developing innovative treatments for blood diseases, including leukemia and lymphoma. Established in 2013, the company focuses on harnessing adult hemogenic endothelial cells to produce cancer-free hematopoietic stem cells for transplantation. This approach aims to enhance the effectiveness of bone marrow transplants while eliminating the reliance on donor sources. By leveraging this unique cellular technology, HemoGenyx seeks to significantly improve patient outcomes in the treatment of blood cancers.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on immuno-oncology and the development of innovative therapies for cancer management. The company’s lead candidate, Bria-IMT, is a targeted cell-based immunotherapy derived from a breast cancer cell line, currently undergoing a Phase I/IIa clinical trial in combination with immune checkpoint inhibitors for advanced breast cancer. BriaCell has achieved positive proof-of-concept for Bria-IMT in this patient population. Additionally, the company is developing Bria-OTS, an off-the-shelf personalized immunotherapy aimed at advanced breast cancer, as well as BriaDx, a diagnostic test. BriaCell Therapeutics is headquartered in West Vancouver, Canada, and collaborates with the National Cancer Institute to advance its research initiatives.

PolyPhotonix is a bio-photonic research and development company specializing in non-invasive medical devices that harness organic light technology. Based at the National Printable Electronics Centre, the company collaborates with designers and key customers to create innovative products for light therapy treatments, particularly aimed at addressing macular eye diseases such as diabetic retinopathy. By focusing on monitored home care solutions, PolyPhotonix aims to empower patients with effective treatment options that can help prevent and manage these conditions.